A long-term follow-up study of 82 children with acute myeloid leukemia

A long-term follow-up study of 82 children with acute myeloid leukemia

Objective: To investigate the efficacy and the prognostic factors of Chinese Academy of Medical Sciences 2005 (CAMS-2005) regimen in the treatment of pediatric acute myeloid leukemia (AML). Methods: Eighty-eight cases of newly-diagnosed AML patients, who were treated with the CAMS-2005 regimen from...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 56(2018), 10 vom: 02. Okt., Seite 730-734
1. Verfasser: Ruan, M (VerfasserIn)
Weitere Verfasser: Qi, B Q, Liu, F, Liu, T F, Liu, X M, Chen, X J, Yang, W Y, Guo, Y, Zhang, L, Zou, Y, Chen, Y M, Zhu, X F
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:Journal Article Observational Study Child Follow-up studies Leukemia, myeloid, acute
LEADER 01000caa a22002652 4500
001 NLM289286123
003 DE-627
005 20250224052815.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.issn.0578-1310.2018.10.003  |2 doi 
028 5 2 |a pubmed25n0964.xml 
035 |a (DE-627)NLM289286123 
035 |a (NLM)30293275 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Ruan, M  |e verfasserin  |4 aut 
245 1 2 |a A long-term follow-up study of 82 children with acute myeloid leukemia 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 01.04.2019 
500 |a Date Revised 01.04.2019 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To investigate the efficacy and the prognostic factors of Chinese Academy of Medical Sciences 2005 (CAMS-2005) regimen in the treatment of pediatric acute myeloid leukemia (AML). Methods: Eighty-eight cases of newly-diagnosed AML patients, who were treated with the CAMS-2005 regimen from April 2005 to July 2009, were enrolled in this case observational study. Clinical characteristics, long-term prognosis and prognostic factors were analyzed retrospectively. Overall survival (OS) and event free survival (EFS) rates were estimated by the Kaplan-Meier method. Rates of survival between the groups were compared by the Log-rank test. Prognostic factors were evaluated by COX regression analysis. Results: A total of 82 cases were enrolled in this study, including 34 core binding factor(CBF)-AML patients and 48 non-CBF-AML patients. There were 45 males and 37 females. The median age at diagnosis was 8.0 (0.7-16.0) years. During the induction therapy, 3 patients (4%) developed treatment-related early-death, while 63 patients (77%) achieved complete remission (CR) and 53 patients (65%) achieved CR after 1 course. Twenty-one patients (33%) had relapsed disease. The CR rates of CBF-AML patients and non-CBF-AML patients were 91% (31/34) and 67% (32/48) (χ(2)=5.410, P=0.020) , while the relapse rates were 29% (9/31) and 38% (12/32) (χ(2)=0.508, P=0.476) . The 8-year OS and EFS rates of all 82 patients were 59%(48/82) and 51%(42/82). The 8-year OS rates of CBF-AML patients and non-CBF-AML patients were 74% (25/34) and 48%(23/48) (χ(2)=5.812, P=0.016), while the 8-year EFS rates of CBF-AML patients and non-CBF-AML patients were 71%(24/34) and 38%(18/48) (χ(2)=8.682, P=0.003). There were statistically significant differences between groups. The 8-year OS rates of patients who achieved CR after 1 course and other patients were 68% (36/53) and 46% (12/26) (χ(2)=9.606, P=0.002), while the 8-year EFS rates were 66% (35/53) and 27% (7/26) (χ(2)=19.471, P=0.000), the differences were all statistically significant. COX multivariate analysis showed that CBF-AML or non-CBF-AML and whether achieved CR after 1 course were independent prognostic factors of OS rates (relative risk: 2.538, 2.561) and EFS rates (relative risk: 3.050, 3.686) (P <0.05). Conclusions: The efficacy of the CAMS-2005 regimen in the treatment of AML patients was well. CBF-AML or non-CBF-AML and whether achieved CR after 1 course were independent prognostic factors for pediatric AML patients 
650 4 |a Journal Article 
650 4 |a Observational Study 
650 4 |a Child 
650 4 |a Follow-up studies 
650 4 |a Leukemia, myeloid, acute 
700 1 |a Qi, B Q  |e verfasserin  |4 aut 
700 1 |a Liu, F  |e verfasserin  |4 aut 
700 1 |a Liu, T F  |e verfasserin  |4 aut 
700 1 |a Liu, X M  |e verfasserin  |4 aut 
700 1 |a Chen, X J  |e verfasserin  |4 aut 
700 1 |a Yang, W Y  |e verfasserin  |4 aut 
700 1 |a Guo, Y  |e verfasserin  |4 aut 
700 1 |a Zhang, L  |e verfasserin  |4 aut 
700 1 |a Zou, Y  |e verfasserin  |4 aut 
700 1 |a Chen, Y M  |e verfasserin  |4 aut 
700 1 |a Zhu, X F  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 56(2018), 10 vom: 02. Okt., Seite 730-734  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:56  |g year:2018  |g number:10  |g day:02  |g month:10  |g pages:730-734 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.issn.0578-1310.2018.10.003  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 56  |j 2018  |e 10  |b 02  |c 10  |h 730-734